The antineoplastic agent of the topoisomerase I inhibitor class, in combination with 5-fluorouracil and leucovorin, is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Irinotecan features the company’s PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors, the company said.
The Irinotecan has approximately $28m sales in the US market for twelve-months ended March 2012, according to IMS data.